Information Provided By:
Fly News Breaks for December 30, 2019
AXSM
Dec 30, 2019 | 15:47 EDT
BTIG analyst Robert Hazlett increased his probability of success to 85% from 75% and his peak U.S. sales estimate to over $300M from $175M for AXS-07 for the treatment of acute migraine after Axsome announced positive data from its Phase 3 MOMENTUM study. Hazlett raised his price target on Axsome shares to $114 from $97 and keeps a Buy rating on the stock.
News For AXSM From the Last 2 Days
There are no results for your query AXSM
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.